Government regulators warn consumers about Abilify

On May 3, 2016, the Food and Drug Administration (FDA) warned that some people using the antipsychotic drug Abilify® have reported compulsive or uncontrollable urges to gamble, eat, shop, or have sex. [1] The FDA is requiring manufacturers to add new warnings about these compulsive behaviors to Abilify drug labels and patient Medication Guides. [2] In 2012, European regulators required the makers of Abilify to warn consumers about the risk of uncontrollable impulses to gamble while taking the drug. [3] Canadian regulators required a similar warning last year. [4] For some patients, the serious, harmful side effects of Abilify have led to large debt, family problems, job loss, and legal problems. Despite government warnings, cases and studies confirming these side effects continue to date.

Robins Kaplan LLP filed the first Abilify compulsive gambling cases in the United States in January 2016 and is actively litigating Abilify compulsive behavior cases. Robins Kaplan LLP has over 20 cases pending in federal courts across the country and 12 cases pending in New Jersey state court.

How the Robins Kaplan team can help

At Robins Kaplan LLP, we investigate potential claims on behalf of Abilify patients to determine whether they have an Abilify lawsuit case. Our firm includes attorneys experienced in pharmaceutical lawsuits like ones against the makers of Abilify. We are careful listeners, and your story is important to us. Our on-staff medical advisors are available to answer your questions and listen to your concerns as you determine what to do next. If you think you or a loved one has been injured by Abilify, we are interested in hearing what you have to say.

For a free case evaluation, please contact us at 1.800.553.9910 (toll-free) or fill out this form. We handle cases in all 50 states. Our legal nurse consultants are standing by.

What is Abilify? You should understand the facts.

Since 2002, doctors have prescribed Abilify, also known as aripiprazole, to treat mental health disorders such as schizophrenia, bipolar disorder, and depression. Sometimes, doctors prescribe Abilify for patients along with an antidepressant (called a serotonin reuptake inhibitor) for more severe depressive disorders. Abilify was developed and manufactured by Otsuka Pharmaceutical Co., headquartered in Japan, and Bristol-Myers Squibb, headquartered in New York.

Abilify can have dangerous and harmful side effects

Some patients who take Abilify have reported irresistible urges to gamble, have sex, shop, or overeat—all related to decreased impulse control. Their out-of-control, obsessive behavior can have devastating consequences:

  • They bet money on card games, sporting events, lotteries, slot machines etc.
  • Win or lose, they continue to gamble, and then borrow to feed their uncontrollable urge to continue.
  • They become preoccupied with gambling; gambling and getting money to continue gambling consumes their lives.
  • Savings are wasted; debts pile up.
  • Family, friends, and work responsibilities, once priorities, fall victim.

Consumers may be entitled to compensations from Abilify manufacturers

The law requires drug makers to inform the public about any damaging side effects of drugs they create and market. Patients who have experienced harmful side effects of Abilify have filed lawsuits, alleging that the manufacturers knew of the side effects, but withheld the information from consumers or downplayed the harm. 

Patients (or, in some cases, their estates) allege that the makers of Abilify should compensate them for their financial losses and emotional trauma:

  • Depleted savings
  • Debt
  • Family problems, such as divorce
  • Legal consequences, such as home foreclosure or bankruptcy
  • Lost jobs, wages, and benefits
  • Pain and suffering
  • Damaged reputation
  • Past and future medical treatment expenses for compulsive behaviors

Explore your right to compensation

If you or someone you know has been prescribed Abilify and has developed a compulsive gambling addiction, you may have an Abilify claim or an Abilify lawsuit. Please contact us at 1.800.553.9910. Our dedicated team of attorneys is experienced in drug-related lawsuits.

[1]FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada), May 3, 2016;


[3]European Medicines Agency, Abilify: Procedural steps taken and scientific information after the authorization (last updated Dec. 6, 2014), available at

[4]Safety information for antipsychotic drug Abilify and risk of certain impulse-control behaviors, Health Canada, Nov. 2, 2015,; Summary Safety Review - ABILIFY and ABILIFY MAINTENA (aripiprazole) - Evaluating the Risk of Certain Impulse Control Behaviours, Health Canada, Nov. 2, 2015,